Prospective study of indoleamine 2,3-dioxygenase activity by mesenchymal stem cell in acute GVHD treatment

Prospective study of indoleamine 2,3-dioxygenase activity by mesenchymal stem cell in acute GVHD treatment - Prospective study of indoleamine 2,3-dioxygenase activity by mesenchymal stem cell in acute GVHD treatment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053400

Enrollment

Registered

2024-01-22

Start date

2020-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute graft-versus-host disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who have undergone allogeneic hematopoietic stem cell transplantation and have neutrophil engraftment. (2) Patients for whom serum from the time of engraftment is stored. (3) Patients who are 16 years of age or older at the time of informed consent. (4) Patients who are expected to receive systemic administration of steroids in case of Grade 2 or higher acute GVHD. (5) Patients who may receive TEMCELL for the treatment of acute GVHD. (6) Patients whose written informed consent for participation in this study is obtained.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of previous administration of TEMCELL. (2) Patients who are not scheduled to receive TEMCELL at the dosage and administration according to the attached document. (3) Other patients who are judged to be unsuitable for the indication by the physician's judgment.

Design outcomes

Primary

Measure	Time frame
IDO activity at each measurement time point from the time of engraftment.	—

Countries

Japan

Contacts

Public ContactJunichi Kitagawa

Gifu municipal hospital Hematology

jkitagawa1128@gmail.com0582511101

Outcome results